EN DE
Watch Oxford Nanopore Technologies Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Oxford Nanopore Technologies Ltd (ONT) fair value: what the stock is really worth

As of Nov 2, 2026: fair value (intrinsic value) of Oxford Nanopore Technologies Ltd stock £0.27, price £2.13, that is 87.3% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BP6S8Z30

ON Oxford Nanopore Technologies Ltd logo Thin data Oct 30, 2026

Oxford Nanopore Technologies Ltd

ONT · LSE
Solid, but very expensive

Our calculation puts a fair price 87% below what the stock costs today.

Low debt
Quality 50/100
Mixed Growth (revenue 5y +14.5 %/yr in GBP)
Fair value £0.2700 · Strongly overvalued (−87.3%)
Loss-making · -51.7% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 15/100 · thin data
Insider activity 35/100
Thin data
Watch Oxford Nanopore Technologies Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£7.16 £0.8655 Fair Value £0.2700 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

60‑month range £0.8655 – £7.16 · fair‑value band £0.1800 – £0.3300 · the £2.13 price screens above the £0.2700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.

Follow Oxford Nanopore Technologies in your weekly email

Every Wednesday you see whether Oxford Nanopore Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry.

Show moreShow less

It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions.

It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008.

Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

Stock analysis

Oxford Nanopore Technologies Ltd (ONT) currently trades at £2.13, while our model-based Fair Value estimate is £0.2700, 87.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: £0.1800 (bear) to £0.3300 (bull), the price of £2.13 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Oxford Nanopore Technologies Ltd reported revenue of £224M in FY2025 versus £134M in FY2021, a compound +13.8%/yr. Reported net income was −£145M in FY2025.

Key figures

Market cap £2.1B Mid · P/S ratio 9.42 · EPS (TTM) £−0.1300 · Net margin −51.7% · Return on equity −25.6% · Return on assets (EBIT) −19.7% · Operating margin −43.5% · Revenue (TTM) £235M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 104% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, ONT screens richer than that median.

Fair Value models

Bear £0.1800 Fair Value £0.2700 Bull £0.3300
Price £2.13 · Downside -87.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) £0.1800 £0.2700 £0.3300 55
All 1 models by family
Asset-Based
NCAV (Graham) £0.1800 £0.2700 £0.3300 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 90
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Start year 2020 (pandemic). Over 10 years: +76.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.2% (2020) → −69.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ONT screens overvalued: fair value 87% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oxford Nanopore Technologies Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 556 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −87.3% · Bottom 25%
Profitability
Return on assets −23.3% · Below median
Net margin (12 months) −51.7% · Bottom 25%
Operating margin (12 months) −43.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 10.5% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.46× · Priciest 25%
P/S (12 months) 8.79× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)53 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $927.89 $1,275 +37% vs ONT
Genmab A/S GMAB kr 3,698 kr 4,303 +16% vs ONT
Samsung Biologics Co 207940 1,422,000 KRW 1,635,700 KRW +15% vs ONT
WuXi Biologics (Cayman) Inc 2269 HK$44.60 HK$49.57 +11% vs ONT
Vertex Pharmaceuticals Incorporated VRTX $558.88 $614.77 +10% vs ONT
argenx SE ARGX $892.87 $908.40 +2% vs ONT
CSL Limited CSL A$201.16 A$178.62 −11% vs ONT
BeOne Medicines AG ONC $370.33 $254.12 −31% vs ONT
Celltrion, Inc 068270 192,000 KRW 74,945 KRW −61% vs ONT
Royalty Pharma plc RPRX $67.18 $19.01 −72% vs ONT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oxford Nanopore Technologies Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Oxford Nanopore Technologies Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ONT.LSE

Frequently asked questions

Is Oxford Nanopore Technologies Ltd (ONT) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of £0.2700 versus a price of £2.13, about 87% lower (overvalued).
What is the fair value of ONT?
Our model-based fair value for Oxford Nanopore Technologies Ltd is £0.2700 (as of Oct 30, 2026), built from audited fundamentals. The current price: £2.13.
What is the quality score of ONT?
Oxford Nanopore Technologies Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oxford Nanopore Technologies Ltd (ONT)?
Our model-based price target is the fair value of £0.2700 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario £0.1800, optimistic scenario £0.3300. It is a calculation from audited fundamentals, not an analyst target.
What is the Oxford Nanopore Technologies Ltd stock forecast for 2026?
Our models put fair value at £0.2700, about 87% lower versus a price of £2.13 (overvalued). Cautious scenario £0.1800, optimistic scenario £0.3300. The calculation is refreshed regularly with new filings.
What is the revenue of Oxford Nanopore Technologies Ltd (ONT)?
Oxford Nanopore Technologies Ltd reported trailing-twelve-month revenue of about £235M (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Oxford Nanopore Technologies Ltd (ONT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oxford Nanopore Technologies Ltd it is £0.2700 per share (as of Oct 30, 2026), against a price of £2.13. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Oxford Nanopore Technologies Ltd stock overvalued or undervalued in 2026?
As of Oct 30, 2026, ONT trades above its calculated fair value: price £2.13, fair value £0.2700, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONT?
No. The price is what the market pays today (£2.13); the fair value is what the company's own numbers justify (£0.2700). For Oxford Nanopore Technologies Ltd the two are £1.86 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oxford Nanopore Technologies Ltd worth?
The market values Oxford Nanopore Technologies Ltd at about £2.1B (market capitalisation, as of Oct 30, 2026). Per share that is £2.13; our models calculate a fair value of £0.2700 per share.
What do the bullish and bearish scenarios say about ONT?
Our models span a range for Oxford Nanopore Technologies Ltd: cautious scenario £0.1800, base £0.2700, optimistic £0.3300 per share (as of Oct 30, 2026, price £2.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oxford Nanopore Technologies Ltd (ONT)?
Balance-sheet figures for Oxford Nanopore Technologies Ltd (as of Oct 30, 2026): return on equity −25.6%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is ONT from its 52-week high?
Oxford Nanopore Technologies Ltd trades at £2.13, about 9% below its 52-week high of £2.35 and 104% above the low of £1.05 (as of Nov 2, 2026). Distance from the high says nothing about value: that is what the fair value of £0.2700 is for.
Which stocks are comparable to Oxford Nanopore Technologies Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oxford Nanopore Technologies Ltd stock attractive at the current price?
The data as of Oct 30, 2026: price £2.13, calculated fair value £0.2700 (−87%), Quality Score 50/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONT calculated?
We run Oxford Nanopore Technologies Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.2700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Oxford Nanopore Technologies Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oxford Nanopore Technologies Ltd (ONT)?
The closing price on Nov 2, 2026 was £2.13. Our model-based fair value is £0.2700, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oxford Nanopore Technologies Ltd right now?
The price sits above even our optimistic bull case (£0.3300). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (£0.1800 to £0.3300) leaves room in how you read the outcome.

Key figures of Oxford Nanopore Technologies Ltd

How large is the market capitalisation of Oxford Nanopore Technologies Ltd (ONT)?
The market capitalisation of Oxford Nanopore Technologies Ltd is £2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oxford Nanopore Technologies Ltd (ONT)?
The price-to-sales ratio of Oxford Nanopore Technologies Ltd is 9.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oxford Nanopore Technologies Ltd (ONT)?
Earnings per share at Oxford Nanopore Technologies Ltd are £−0.1300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oxford Nanopore Technologies Ltd (ONT)?
The net margin of Oxford Nanopore Technologies Ltd is −51.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oxford Nanopore Technologies Ltd (ONT)?
The return on equity (ROE) of Oxford Nanopore Technologies Ltd is −25.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oxford Nanopore Technologies Ltd (ONT)?
On an EBIT basis the return on assets of Oxford Nanopore Technologies Ltd is −19.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oxford Nanopore Technologies Ltd (ONT)?
The operating margin of Oxford Nanopore Technologies Ltd is −43.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oxford Nanopore Technologies Ltd (ONT)?
Revenue at Oxford Nanopore Technologies Ltd is growing +10.5% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Oxford Nanopore Technologies Ltd (ONT) generate?
The free cash flow of Oxford Nanopore Technologies Ltd is −£66.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oxford Nanopore Technologies Ltd (ONT) hold?
Oxford Nanopore Technologies Ltd holds more cash than debt, £140M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Oxford Nanopore Technologies Ltd in the live analysis

One click puts Oxford Nanopore Technologies Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.